Dose response of PTH and FGF23 to paricalcitol in patients with end-stage renal failure on chronic intermittent hemodialysis
Clinical Nephrology · 2026
DOI: 10.5414/cn111768 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Nephrology, 2026. Verfasst von Nicolaus Mussmaecher und 6 weiteren Autor:innen. Hauptthemen laut MEDLINE: Ergocalciferols, Fibroblast Growth Factors, Renal Dialysis, Parathyroid Hormone.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Mussmaecher, N., Mitzner, S., Haas, C., Busch, M., Ketteler, M., Wanner, C., & Biggar, P. (2026). Dose response of PTH and FGF23 to paricalcitol in patients with end-stage renal failure on chronic intermittent hemodialysis. Clinical Nephrology. https://doi.org/10.5414/cn111768
Vancouver
Mussmaecher N, Mitzner S, Haas C, Busch M, Ketteler M, Wanner C, et al. Dose response of PTH and FGF23 to paricalcitol in patients with end-stage renal failure on chronic intermittent hemodialysis. Clinical Nephrology. 2026. doi:10.5414/cn111768
BibTeX
@article{Mussmaecher2026,
author = {Mussmaecher, Nicolaus and Mitzner, Steffen and Haas, Christian and Busch, Martin and Ketteler, Markus and Wanner, Christoph and Biggar, Patrick},
title = {Dose response of PTH and FGF23 to paricalcitol in patients with end-stage renal failure on chronic intermittent hemodialysis},
journal = {Clinical Nephrology},
year = {2026},
doi = {10.5414/cn111768}
}
EUVIMED